Proton versus photon therapy for esophageal cancer - A trimodality strategy (PROTECT) NCT050555648: A multicenter international randomized phase III study of neoadjuvant proton versus photon chemoradiotherapy in locally advanced esophageal cancer.

Authors :: Mortensen HR
Populaire P
Hoffmann L
Moeller DS
Appelt A
Nafteux P
Muijs CT
Grau C
Hawkins MA
Troost EGC
Defraene G
Canters R
Clarke CS
Weber DC
Korevaar EW
Haustermans K
Nordsmark M
Gebski V
Achiam MP
Markar SR
Radhakrishna G
Berbee M
Scartoni D
Orlandi E
Doyen J
Gregoire V
Crehange G
Langendijk J
Lorgelly P
Blommenstein HM
Byskov CS
Ehmsen ML
Jensen MF
Freixas GV
Bütof R
Source :: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology [Radiother Oncol] 2024 Jan; Vol. 190, pp. 109980. Date of Electronic Publication: 2023 Nov 05.
Publication Year :: 2024
Abstract: Competing Interests: Declaration of competing interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: [Hanna Rahbek Mortensen is Co-chair of Patient Involvement Work Package in PROTECT.].

Subjects :: Humans
Chemoradiotherapy
Esophagectomy
Protons
Clinical Trials, Phase III as Topic
Randomized Controlled Trials as Topic
Multicenter Studies as Topic
Esophageal Neoplasms surgery
Neoadjuvant Therapy

Language :: English
ISSN :: 1879-0887
Volume :: 190
Database :: MEDLINE
Journal :: Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Publication Type :: Editorial & Opinion
Accession number :: 37935284
Full Text :: https://doi.org/10.1016/j.radonc.2023.109980

Full Text Access

Tools